Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non-Current Liabilities (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 326.94% year-over-year to $8.4 million, compared with a TTM value of $8.4 million through Dec 2025, up 326.94%, and an annual FY2025 reading of $8.4 million, up 326.94% over the prior year.
  • Other Non-Current Liabilities was $8.4 million for Q4 2025 at Xeris Biopharma Holdings, up from $3.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $30.1 million in Q3 2022 and bottomed at $31000.0 in Q1 2023.
  • Average Other Non-Current Liabilities over 5 years is $7.7 million, with a median of $5.0 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities crashed 94.63% in 2023, then soared 3193.55% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $22.5 million in 2021, then grew by 14.01% to $25.7 million in 2022, then plummeted by 94.63% to $1.4 million in 2023, then soared by 42.64% to $2.0 million in 2024, then skyrocketed by 326.94% to $8.4 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for XERS at $8.4 million in Q4 2025, $3.4 million in Q3 2025, and $7.8 million in Q2 2025.